Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $231.80

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given a consensus rating of “Buy” by the seventeen brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $229.1250.

A number of equities research analysts recently commented on the stock. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Jefferies Financial Group dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a research report on Friday, February 6th. Finally, Citigroup reduced their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently modified their holdings of the company. Eubel Brady & Suttman Asset Management Inc. purchased a new position in IQVIA during the third quarter worth about $14,278,000. OPTIMAS CAPITAL Ltd acquired a new position in shares of IQVIA during the 3rd quarter valued at about $4,008,000. Eagle Rock Investment Company LLC increased its stake in shares of IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after acquiring an additional 11,657 shares during the last quarter. Amundi lifted its holdings in shares of IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the period. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in shares of IQVIA in the third quarter worth approximately $7,368,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE IQV opened at $174.34 on Monday. The business has a 50 day moving average price of $207.22 and a 200 day moving average price of $207.58. The company has a market capitalization of $29.59 billion, a P/E ratio of 22.18, a PEG ratio of 1.68 and a beta of 1.39. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.During the same period in the previous year, the business earned $3.12 earnings per share. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.